CSF biomarker variability in the Alzheimer's Association quality control program
- Mattsson, Niklas
- Andreasson, Ulf
- Persson, Staffan
- Carrillo, Maria C.
- Collins, Steven
- Chalbot, Sonia
- Cutler, Neal
- Dufour-Rainfray, Diane
- Fagan, Anne M.
- Heegaard, Niels H. H.
- Robin Hsiung, Ging-Yuek
- Hyman, Bradley
- Iqbal, Khalid
- Lachno, D. Richard
- Lleó, Alberto
- Lewczuk, Piotr
- Molinuevo, José L.
- Parchi, Piero
- Regeniter, Axel
- Rissman, Robert
- Rosenmann, Hanna
- Sancesario, Giuseppe
- Schröder, Johannes
- Shaw, Leslie M.
- Teunissen, Charlotte E.
- Trojanowski, John Q.
- Vanderstichele, Hugo
- Vandijck, Manu
- Verbeek, Marcel M.
- Zetterberg, Henrik
- Blennow, Kaj
- Käser
- Stephan A.
- Andreasson U
- Persson S
- Arai H
- Batish SD
- Bernardini S
- Bocchio-Chiavetto L
- Blankenstein MA
- Carrillo MC
- Chalbot S
- Coart E
- Chiasserini D
- Cutler N
- Dahlfors G
- Duller S
- Fagan AM
- Forlenza O
- Frisoni GB
- Galasko D
- Galimberti D
- Hampel H
- Handberg A
- Heneka MT
- Herskovits AZ
- Herukka SK
- Holtzman DM
- Humpel C
- Hyman BT
- Iqbal K
- Jukcer M
- Kaeser SA
- Kaiser E
- Kapaki E
- Kidd D
- Klivenyi P
- Knudsen CS
- Kummer MP
- Lui J
- Lladó A
- Lewezuk P
- Li QX
- Martins R
- Masters C
- McAuliffe J
- Mercken M
- Moghekar A
- Molinuevo JL
- Montine TJ
- Nowatzke W
- O'Brien R
- Otto M
- Paraskevas GP
- Parnetti L
- Petersen RC
- Prvulovic D
- de Reus HP
- Rissman RA
- Scarpini E
- Stefani A
- Soininen H
- Schröder J
- Shaw LM
- Skinningsrud A
- Skrogstad B
- Spreer A
- Talib L
- Teunissen C
- Trojanowski JQ
- Tumani H
- Umek RM
- Van Broeck B
- Vanderstichele H
- Vecsei L
- Verbeek MM
- Windisch M
- Zhang J
- Zetterberg H
- Blennow K.
DOIAbstract
Background: The cerebrospinal fluid (CSF) biomarkers amyloid beta 1-42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient management. However, there are large variations in biomarker measurements among and within laboratories. Methods: Data from the first nine rounds of the Alzheimer's Association quality control program was used to define the extent and sources of analytical variability. In each round, three CSF samples prepared at the Clinical Neurochemistry Laboratory (Mölndal, Sweden) were analyzed by single-analyte enzyme-linked immunosorbent assay (ELISA), a multiplexing xMAP assay, or an immunoassay with electrochemoluminescence detection. Results: A total of 84 laboratories par...
Add to ORKG